Voy UK Review – An Independent Assessment

What is Voy?

Voy is a digital weight loss programme offering prescription weight loss medication alongside app-based support and behaviour change coaching. It is owned by Menwell Ltd, which trades as Manual, a men’s health company that expanded into women’s weight loss with the launch of Voy in 2024.
Despite being relatively new, Voy has grown rapidly. It now claims over 100,000 UK members and has established itself as one of the most price-competitive options in the UK private weight loss market, with entry-level pricing that undercuts most competitors and has driven substantial growth. See our live Mounjaro price comparison for exactly where Voy sits today.
Voy operates entirely digitally. There are no physical clinics. Everything from the initial assessment through to ongoing support happens through the app or online. For weight loss specifically, Voy offers Mounjaro, Wegovy injections and, more recently, the Wegovy tablet.

What is included in the programme

Voy’s programme combines prescription medication with behaviour change support delivered through its app. Members receive access to a health coaching programme focused on building sustainable habits around eating, movement and mindset.
The app includes tools for tracking weight, logging meals, setting goals and accessing educational content. A community element allows members to connect with others on the programme.
Clinical support is available through an in-app messaging system and a phone hotline operating Monday to Friday during business hours, with live chat available seven days a week.
The behaviour change focus is a genuine differentiator. Voy’s approach acknowledges that medication alone does not produce lasting results and attempts to build habits that support long-term weight management. Whether the depth of that support matches what more premium services offer is a fair question, and one covered in the weaknesses section below.
Voy also offers a weight loss money-back guarantee over a 180-day period. It is not all-or-nothing: according to Voy’s own published terms, refunds are pro-rated to how close you get to the 10 percent target – for example, losing 8 percent of your starting body weight would qualify for a 20 percent refund, not a full one. To be eligible you must also not have used prescription weight-loss medication in the 12 months before starting with Voy, and refund claims can only be submitted between day 180 and day 210. The full terms are worth reading carefully before relying on this as a reason to sign up.

The consultation process

The Voy consultation begins with an online medical assessment. You provide information about your height, weight, medical history, current medications and weight loss goals. According to Voy, this is reviewed by a UK-registered prescriber within 24 hours and medication is dispatched within one working day of approval.
Voy states it can prescribe from a BMI of 25 where clinically appropriate. This is worth understanding precisely: Mounjaro and Wegovy are licensed for a BMI of 30+, or 27+ with a weight-related health condition. In a May 2026 investigation by consumer group Which?, Voy confirmed it prescribes from BMI 25 “as standard,” including to people without a weight-related condition, describing this as a “proactive approach to health.” Prescribing below the medicine’s licensed threshold is off-label prescribing – a recognised and lawful clinical practice, but one that normally calls for extra clinical caution, and worth knowing about before you sign up.
As with most digital weight loss services, there is no default video consultation. The assessment is questionnaire-based. This is standard across the sector but worth understanding if you prefer to speak with a clinician before starting treatment. It is also directly relevant to the verification concerns raised by regulators and covered in the weaknesses section below – a questionnaire-based process is only as reliable as the checks behind it.

Pricing breakdown

Voy’s pricing remains one of its most distinctive features, though it is no longer the only price-competitive option in the UK market – as of September 2026, some newer providers, including Bolt Pharmacy, have introduced starter pricing that sits close to or below Voy’s headline rate. See our independent Mounjaro price comparison for live, up to date figures across every major UK provider, since specific prices change often and the cheapest option shifts regularly.
It is important to understand what drives Voy’s headline pricing. Voy offers different plan lengths, monthly rolling, three month, six month and twelve month plans. Longer commitments typically come with lower monthly prices. The lowest advertised figures reflect specific dose and plan combinations rather than a flat monthly cost at all doses.
As doses increase through the standard titration schedule, monthly costs rise. Higher maintenance doses of Mounjaro at 12.5mg or 15mg will cost meaningfully more than the starter price. Checking the full pricing schedule for the specific dose you are likely to reach over time is important before committing.
Wegovy injection pricing follows a similar structure with lower introductory prices on longer plans. The Wegovy tablet, added to Voy’s programme in July 2026, is priced separately and is generally cheaper at starter doses than either injection, see our live Wegovy price comparison for current figures.

The good – genuine strengths

Voy’s pricing makes prescription weight loss treatment accessible to a broader range of UK women than higher-priced competitors. For people priced out of some established providers but wanting access to licensed medications, Voy fills a genuine gap in the market.
The speed of the consultation and dispatch process is consistently praised in patient feedback. According to Voy, assessments are reviewed within 24 hours and medication dispatched within one working day. Many reviewers confirm this timeline in practice.
The lower BMI threshold means Voy can help people who do not meet the stricter licensed eligibility criteria of NHS services or some private competitors, though as covered above, this involves off-label prescribing worth understanding fully first.
The money-back guarantee, while conditional and pro-rata rather than all-or-nothing, demonstrates a level of confidence in outcomes that most competitors do not offer. For people who are uncertain whether the treatment will work for them, this reduces the financial risk of trying it.
The rapid growth to over 100,000 members suggests the model is working for a large number of UK patients, and Voy’s Trustpilot rating is consistently strong (4.7 out of 5 from over 25,000 reviews as of September 2026), check the current score directly on Trustpilot for the latest figure, since review counts and scores shift regularly.

The not so good – honest weaknesses

Voy and its parent company Menwell Ltd have built up an extended regulatory history since 2025 – considerably more than a single incident – and, separately and more seriously, have been the subject of independent journalism questioning how robustly Voy verifies who it is prescribing to. This section requires full, honest treatment rather than a single headline finding.

Advertising rulings. Voy has faced several upheld ASA rulings and MHRA interventions since mid-2025. The most significant and most recent include: in December 2025, the MHRA found that a sponsored social media advertisement for Orlos (an over-the-counter weight loss product) used misleading price references and displayed the image and signature of Voy’s Chief Medical Officer in a way that implied medical endorsement, while also linking to promotional information about prescription-only weight loss medicines. Voy agreed to amend its marketing and confirmed compliance. Read the December 2025 MHRA decision.
In February 2026, the ASA separately banned a series of Instagram posts in which customers and affiliates used discount codes and “before and after” photos to promote Mounjaro through a referral scheme that Voy operated and controlled. Read the February 2026 ASA ruling.
In May 2026, the ASA upheld a further complaint that Voy’s “Black Friday” emails pressured recipients into signing up for medicated weight loss using time-limited discounts, ruling this had not been prepared in a socially responsible manner. Read the May 2026 ASA ruling.
In August 2026, the MHRA issued a second finding against Voy, again over Orlos advertising, this time concerning “coming soon” and “presale waitlist” language the regulator considered misleading in reference to an unlicensed weight loss medicine. Read the August 2026 MHRA decision. You can see the ASA’s full ruling history for Menwell Ltd by searching “Menwell Ltd” at asa.org.uk/rulings.

A more serious concern: prescribing verification. In February 2026, a BBC News investigation found that Voy (along with MedExpress) approved a test order for weight-loss injections submitted with inaccurate personal details and an outdated photo, with no further verification requested before the medication was dispatched. The General Pharmaceutical Council, which regulates dispensing pharmacies, investigated both firms and said it was “very concerned” by the findings. Separately, a Which? investigation published on 20 May 2026 reported a similar outcome for Voy (alongside Superdrug, MedExpress and Zava), with medication issued despite a fabricated GP address and a false medical claim. On this occasion the GPhC did not open a Voy-specific probe; its response to Which? was that it was “concerned about the inappropriate prescribing… found by Which?” and would “consider these findings as part of our ongoing review of emerging issues and risks in this area” – a sector-wide review rather than an enforcement action against Voy alone. Taken together, this is a materially different, and more serious, category of concern than the advertising rulings above – it relates directly to whether Voy’s clinical checks are robust enough to stop ineligible people accessing prescription medication. Voy has stated it has since updated its verification processes, and its Chief Medical Officer told the BBC that all treatments are “prescribed only following a thorough medical assessment by UK-registered clinicians.” Readers weighing up whether to sign up should factor this in alongside the advertising record, not read it as a separate, lesser issue.

A further concern is the depth of coaching support. Compared to more established services, some reviewers note that the behaviour change programme feels less intensive than described. For people who want substantial one-to-one coaching input, Voy’s offering may not match expectations set by the marketing.
The customer service response time outside business hours receives criticism in some reviews. Live chat is available seven days a week but some members report delays during busy periods, and some 2026 Trustpilot reviews describe ongoing account and billing issues following Voy’s systems integration with Manual.
The conditions attached to the money-back guarantee are worth reading carefully. Eligibility requirements apply and the process for claiming a refund is not always described as straightforward.

Who Voy suits best

Voy works well for people who prioritise price and want licensed medication at an accessible cost in the UK private market. It suits people who are comfortable with a largely self-directed digital programme and do not require intensive coaching or close clinical oversight.
It is also a reasonable option for people who have a BMI between 25 and 30 and cannot access treatment through services with higher eligibility thresholds.
The money-back guarantee appeals to people who want to try treatment with reduced financial risk.

Who Voy probably does not suit

Voy is less suitable for people who want intensive one-to-one coaching support, close clinical oversight or a service with a longer, cleaner regulatory track record. People who prefer face-to-face or video consultations will not find that here.
Voy’s extended regulatory history, and particularly the BBC and Which? findings on prescribing verification, will concern people who place significant weight on a provider’s compliance and safety record. Taken together, these developments give prospective patients considerably more regulatory history to weigh than a single incident would suggest, and it is a reasonable, material factor in any decision.
People who need support outside standard business hours may find the clinical support model limiting.

How to verify Voy is legitimate

Before signing up to any private weight loss service, three checks protect you.
CQC registration: Voy’s provider, Menwell Limited, is listed on the Care Quality Commission register – the listing itself is titled “Also known as Manual & Voy.” It is registered, which is a genuine and necessary step, but worth knowing precisely what that means: as of September 2026, none of Menwell’s registered locations have yet been inspected or rated by the CQC. “Registered, not yet inspected” is normal for newer services and is not on its own a red flag, but it does mean there is no independent CQC quality rating to check yet, only the registration itself.
GPhC registration: Confirm that Voy’s dispensing pharmacy is registered with the General Pharmaceutical Council at pharmacyregulation.org. The GPhC has responded to two separate 2026 media investigations into Voy’s prescribing checks (detailed in the weaknesses section above) – it investigated Voy directly following the BBC’s findings, and separately said it was concerned by the Which? findings and would fold them into its ongoing sector-wide review, rather than opening a dedicated investigation into Voy for that report specifically.
Regulatory decisions: You can read the full record of MHRA and ASA rulings against Menwell Ltd/Voy directly – search gov.uk for “promotion of medicinal products for weight loss by Menwell Ltd” for the MHRA decisions, or asa.org.uk/rulings for “Menwell Ltd” for the full ASA history. Direct links to the most significant recent decisions are included in the weaknesses section above.

Verdict

Voy is a legitimate, CQC-registered service offering licensed weight loss medications at some of the most competitive prices available in the UK private market. For people who cannot afford higher-priced alternatives and want access to Mounjaro or Wegovy, it represents a real and regulated option.
The caveats here have grown more significant since this review was first published, and deserve honest weighing rather than a passing mention. Voy’s extended history of upheld ASA and MHRA advertising rulings since 2025 means the December 2025 case should not be viewed in isolation. More importantly, independent BBC and Which? investigations in 2026 both found gaps in how thoroughly Voy verifies who it is prescribing to – a clinical safety question, not just a marketing one – which the GPhC has responded to with direct investigation in one case and stated concern in the other. Voy also prescribes below the medicines’ licensed BMI threshold as standard practice, which is lawful but is off-label prescribing worth understanding fully. The coaching support, while genuine, may not match the depth suggested in marketing materials. And the headline pricing requires careful scrutiny and comparison with current alternatives – the cost at higher maintenance doses will be meaningfully higher than the entry-level figure, and Voy is no longer definitively the cheapest option on the market.
For price-conscious patients who want licensed medication with basic support and are comfortable with a largely self-directed digital programme, Voy remains worth considering, provided you go in with eyes open about its regulatory record. For patients who want the deepest clinical oversight, the strongest coaching support, or a provider with a clean and consistent compliance record, alternatives may better suit those priorities. You can also compare our Numan review and Superdrug Wegovy review before deciding.

Frequently Asked Questions

This review is for information purposes only. ThePeptideBrief does not receive payment from Voy or any other clinic for editorial coverage. Always conduct your own research before committing to any private health service.